NCT00758706 - A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

AZD1236

oral tablet, 75 mg, twice daily during 6 weeks

DRUG

Placebo

Dosing to match AZD1236

Trial Locations (10)

Research Site, Aalborg

Research Site, Arhus C

Research Site, København NV

Research Site, Odense C

Research Site, Helsinki

Research Site, Tampere

Research Site, Eindhoven

Research Site, Nieuwegein

Research Site, Oslo

Research Site, Trondheim